Latest database descriptions

Evaluation of factors influencing use of Roacterma® as monotherapy in Rheumatoid Arthritis patients in a real life setting

February 04 2022

Primary objective : To describe in a real-life setting the factors influencing the use of RoActemra® as monotherapy or in combination with DMARDs in patients with rheumatoid arthritis
Secondary objectives :
- To describe the characteristics of patients treated with RoActemra® as monotherapy or in combination with another treatment.
- To describe impact of physician characteristics on use of RoActemra® as monotherapy or in combination.
- For patients on RoActemra® monotherapy, to describe reasons for discontinuation or non-use of csDMARDs.
- To evaluate treatment maintenance one year after RoActemra® initiation in a real-life setting.
- To describe efficacy of RoActemra® in real conditions of use.
- To describe effect of RoActemra® on quality of life in real conditions of use.
- To assess safety profile of RoActemra® in real conditions of use.

Subcutaneous Tocilizumab in monotherapy or in combination with csDMARD in patients with moderate to severe active Rheumatoid Arthritis and followed by hospital and office-based rheumatologists: Non-interventional study to describe realworld drug retent...

February 04 2022

Primary objective : To assess the drug retention rate of TCZ sc at 12 months under real-world conditions in patients with moderate to severe active RA followed by hospital- and office-based rheumatologists
Secondary objectives :
- To assess the drug retention rate of TCZ sc at 6 and 18 months.
- To compare the drug retention of TCZ sc in monotherapy and in combination with MTX or other csDMARD.
- To describe steroid dosing after introduction of TCZ sc with a stratification on the use of MTX or other csDMARDs at 6, 12 and 18 months.
- To assess adherence to TCZ sc using a French version of the Compliance Questionnaire for Rheumatology 5 (CQR5) and patient diary at 6, 12 and 18 months.
- To evaluate the French version of the CQR5 by assessing the correlation with the data collected from the patient diary data.
- To describe the modalities of use of TCZ sc.
- To describe the management of RA and patients’ healthcare pathway between hospital- and office-based rheumatologists.
- To describe the efficacy of TCZ sc under real-world conditions of use.
- To describe the characteristics of patients treated with TCZ sc and the characteristics of the involved physicians.
- To assess the tolerability profile of TCZ sc under real-world conditions of use.
- To describe the quality of life (QoL) in patients receiving TCZ sc under real-world conditions of use.

Therapeutic strategies including Avastin as 1st line therapy in elderly patients suffering from advanced (IIIB/IV Stage) non-squamous non-small cell lung cancer, in routine clinical practice

February 04 2022

In each cohort of patients defined by their age classification ([65; 70[ and >=70 years), outcome measures are as follows:
- Antineoplastic agents combined with bevacizumab as 1st line therapy
- Classes of antineoplastic agents combined with bevacizumab as 1st line therapy (platinum salt, taxanes,…)
- Supportive care (growth factors, analgesics).
to describe:
- Characteristics of advanced nsNSCLC patients treated with bevacizumab as first-line therapy, and their disease characteristics,
- Progression-Free Survival (PFS) and Overall Survival (OS),
- Evolution of patients’ quality of life over the treatment period with bevacizumab as first-line therapy,
- Safety of bevacizumab,
- Reasons for non-use of bevacizumab as first-line therapy in patients suffering from advanced nsNSCLC.

Prospective cohort study on the impact of insulin resistance on sustained virological response to Pegasys® and Copegus® treatment in patients with Chronic Hepatitis-C

February 04 2022

Primary objective : To describe in real-life conditions the insulin resistance and its impact on SVR in patients presenting with chronic hepatitis C and treated with Pegasys® and Copegus®.
Secondary objectives :
- To describe patients’ characteristics at inclusion
- To describe the predictive factors influencing virological response under treatment at W4 (rapid virological response, RVR), at W12 (early virological response, EVR), and 24 weeks after the end of treatment with Pegasys® (sustained virological response, SVR)
- To describe the constitutive parameters of metabolic syndrome during the study period
- To describe the management of chronic hepatitis C and insulin resistance
- To describe the changes in patients’ quality of life during the study period
- To describe the serious and non-serious adverse events occurring during the study period.

Explore the catalog

The catalog contains the description of the main databases in public health in France

Explore the catalog

Become a contributor

You wish to share the information about your database with researchers and experts in public health?

Become a contributor

Contact us

You have a question? You need more information? 

Send a message

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here